RT Journal Article SR Electronic T1 The association of age-related and off-target retention with longitudinal quantification of [18F]MK6240 tau-PET in target regions JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.05.24.22275386 DO 10.1101/2022.05.24.22275386 A1 Cécile Tissot A1 Stijn Servaes A1 Firoza Lussier A1 João Pedro Ferrari Souza A1 Joseph Therriault A1 Pâmela Cristina Lukasewicz Ferreira A1 Gleb Bezgin A1 Bruna Bellaver A1 Douglas Teixeira Leffa A1 Sulantha S. Mathotaarachchi A1 Jenna Stevenson A1 Nesrine Rahmouni A1 Min Su Kang A1 Vanessa Pallen A1 Nina Margherita-Poltronetti A1 Yi-Ting Wang A1 Jaime Fernandez-Arias A1 Andrea L. Benedet A1 Eduardo R. Zimmer A1 Jean-Paul Soucy A1 Dana L. Tudorascu A1 Annie D. Cohen A1 Madeleine Sharp A1 Serge Gauthier A1 Gassan Massarweh A1 Brian Lopresti A1 William E. Klunk A1 Suzanne L. Baker A1 Victor L. Villemagne A1 Pedro Rosa-Neto A1 Tharick A. Pascoal YR 2022 UL http://medrxiv.org/content/early/2022/05/28/2022.05.24.22275386.abstract AB Introduction [18F]MK6240 is a tau-PET tracer that quantifies brain tau neurofibrillary tangles (NFT) load in Alzheimer’s disease (AD). The aims of our study are to test the stability of common reference regions estimates in the cerebellum over time and across diagnoses and evaluate the effects of age-related and off-target retention in the longitudinal quantification of [18F]MK6240 in target regions.Methods We assessed reference, target, age-related and off-target regions in 125 individuals across the aging and AD spectrum with longitudinal [18F]MK6240 standardized uptake values (SUV) and ratios (SUVR) (2.25± 0.4 years of follow-up duration). We obtained SUVR values from meninges, a region exhibiting frequent off-target retention of [18F]MK6240, as well as compared tracer uptake between cognitively unimpaired young (CUY, mean age: 23.41± 3.3 years) and cognitively unimpaired older adults (CU, amyloid-β and tau negative, mean age: 58.50± 9.0 years) to identify possible, non-visually apparent, age-related signal. Two-tailed t-test and Pearson correlations tested the difference between groups and associations between changes in region uptake, respectively.Results Inferior cerebellar grey (CG) and full CG presented stable SUV cross-sectionally and over time, across diagnosis and Aβ status. [18F]MK6240 uptake was significantly different between CU young and adults mostly in putamen/pallidum (affecting ∼75% of the region) but also in Braak II region (affecting ∼35%), comprised of the entorhinal cortex and hippocampus. Changes in meningeal and putamen/pallidum SUVRs were not significantly different from zero, nor varied across diagnostic groups. We did not observe significant correlations between longitudinal changes in age-related or meningeal off-target retention and changes in target regions, whereas changes in all target regions were highly correlated.Conclusion Inferior and full CG were similar across diagnostic groups cross-sectionally and stable over time, and thus were deemed suitable reference regions for quantification. Despite this not being visually perceptible, [18F]MK6240 has age-related retention in subcortical regions, in much lower magnitude but topographically co-localized with the most significant off-target signal of the first-generation tau tracers. The lack of correlation between changes in age-related/meningeal and target retention suggests little influence of possible off-target signals on longitudinal tracer quantification. On the other hand, the age-related tracer retention in Braak II needs to be further investigated. Future post-mortem studies should elucidate the source of the newly reported age-related [18F]MK6240 signal, and in vivo studies should further explore its impact on tracer quantification.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Weston Brain Institute, Canadian Institute of Health Research, Fonds de Recherche Sante-Quebec and Heatlhy Brains for Healthy lives.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data was acquired at the McGill Center for Studies in Aging, and the project was approved by the Research Ethics Board of the Douglas Mental Health Institute. Written consent has been obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.